Avalyn Pharma Acquisition | Healthcare Deal in MA

Avalyn Pharma has completed the acquisition of a pharmacy business in Massachusetts, for $300 million. Avalyn Pharma is a Boston biotech focused on inhalable drug development for pulmonary fibrosis, including idiopathic and progressive forms. The company aims to improve existing marketed therapies by creating inhalable versions of Ofev and Esbriet to enhance potency and patient usability. As an other acquisition tied to healthcare M&A and MA acquisitions, the $300 million IPO proceeds support a pipeline of lung disease treatments, including an AP01 Phase 2b program. Avalyn Pharma plans to trade on Nasdaq under ticker AVLN after pricing 16.7 million shares at $18.